Literature DB >> 19762163

Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.

Gamze Donmez1, Yurdanur Sullu, Sancar Baris, Levent Yildiz, Oguz Aydin, Filiz Karagoz, Bedri Kandemir.   

Abstract

Angiogenesis is a multistep process that depends on the balance of proangiogenic factors and inhibitors as well as on interactions with the extracellular matrix. We examined the immunohistochemical expression of the defining angiogenic agents, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9), and the antiangiogenic agent thrombospondin-1 (TSP-1) in 131 patients with urothelial carcinoma and correlated their expression levels with clinicopathological parameters. VEGF and MMP-9 expression was higher in high-grade tumors than in low-grade tumors (p=0.000 and p=0.001, respectively), whereas the reverse was true for TSP-1 (p=0.000). VEGF and MMP-9 expression was higher in deeper tumors compared to superficial tumors and in invasive tumors compared to non-invasive tumors (p=0.001 and p=0.001, respectively), while TSP-1 was lower (p=0.000). We could differentiate 22 of 41 muscle-invasive (T2) cases as superficial (T2a; n=7) or deep (T2b; n=15), but no difference was found between them regarding VEGF, MMP-9, or TSP-1 expression (p=0.783, p=0.289, and p=0.783, respectively). There was a positive correlation between VEGF and MMP-9 expression (p=0.008, r=0.23) but a negative correlation between MMP-9 and TSP-1 expression (p=0.014, r=-0.21). Increased VEGF and MMP-9 expression as well as decreased TSP-1 expression may play considerable roles in the invasion and differentiation of urothelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762163     DOI: 10.1016/j.prp.2009.07.015

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  21 in total

1.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

Review 2.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

3.  SLC39A2 and FSIP1 polymorphisms as potential modifiers of arsenic-related bladder cancer.

Authors:  Margaret R Karagas; Angeline S Andrew; Heather H Nelson; Zhongze Li; Tracy Punshon; Alan Schned; Carmen J Marsit; J Steven Morris; Jason H Moore; Anna L Tyler; Diane Gilbert-Diamond; Mary-Lou Guerinot; Karl T Kelsey
Journal:  Hum Genet       Date:  2011-09-25       Impact factor: 4.132

Review 4.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

5.  Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion.

Authors:  Arup Bhattacharya; Yun Li; Kristina L Wade; Joseph D Paonessa; Jed W Fahey; Yuesheng Zhang
Journal:  Carcinogenesis       Date:  2010-10-01       Impact factor: 4.944

6.  Pigment epithelium-derived factor expression is down-regulated in bladder tumors and correlates with vascular endothelial growth factor and matrix metalloproteinase-9.

Authors:  Chen-Chen Feng; Qiang Ding; Yuan-Fang Zhang; Hao-Wen Jiang; Hui Wen; Pao-Hsun Wang; Zhong Wu
Journal:  Int Urol Nephrol       Date:  2010-09-17       Impact factor: 2.370

Review 7.  The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.

Authors:  Paulina Wigner; Radosław Grębowski; Michał Bijak; Joanna Saluk-Bijak; Janusz Szemraj
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

8.  Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.

Authors:  Apostolos Zaravinos; Dimitrios Volanis; George I Lambrou; Dimitris Delakas; Demetrios A Spandidos
Journal:  Oncol Rep       Date:  2012-08-03       Impact factor: 3.906

Review 9.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

10.  Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract.

Authors:  Yasuyoshi Miyata; Shin-ichi Watanabe; Hiroshi Kanetake; Hideki Sakai
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.